Background: Patients at the highest risk of hyperkalemia are those with chronic kidney disease (CKD) stages 3 and 4. Objective: To evaluate the efficacy and safety of patiromer in hyperkalemia in patients with heart failure or CKD. Methods: The Cochrane Renal Group's Specialized Register was searched through contact with the Trials' Search Coordinator. We aimed at including randomized controlled trials with patiromer in patients with developed or risks of developing hyperkalemia, comparing against an active comparator or placebo. Three studies matched our inclusion and exclusion criteria, which we included in the meta-analysis. All-cause mortality, reduction in hospitalization, episodes of hypokalemia or hyperkalemia, and cardiovascular and gastrointestinal adverse events during the treatment period were our primary outcomes. Serial change in serum potassium (K þ ) until end of treatment or follow-up during the trial period and all other reported adverse reactions during the treatment period were our secondary outcomes. Meta-analysis (RevMan version 5.3.5) and descriptive statistics were used. Results: There was a non-significant improvement in all-cause mortality and serious cardiovascular events with patiromer than placebo. Hospitalization data were unavailable. Although serious gastrointestinal events were more common with placebo, there was a significant reduction (P ¼ .02) in the risk of non-serious gastrointestinal events with placebo. Patiromer lowered serum K þ more than placebo, and there were more patients developing hyperkalemia with placebo. High-dose patiromer was associated with better efficacy in some parameters but with more adverse events. Conclusion: Although patiromer seems promising, more trials with active comparator are essential to finalize its indication and use in hyperkalemia.
Introduction

Description of the Condition
Hyperkalemia is associated with life-threatening cardiac arrhythmias and increased mortality. 1 Patients at the highest risk of hyperkalemia are those with stage 3 or higher chronic kidney disease (CKD), with or without diabetes or heart failure, who are being treated with drugs that inhibit renal potassium (K þ ) excretion, particularly inhibitors of the renin-angiotensin-aldosterone system (RAAS). [1] [2] [3] [4] In patients with CKD complicating their heart failure, renal excretion of K þ is compromised and is in part compensated by an increase in colonic excretion, which often is not sufficient to avoid hyperkalemia. 1 Patients with CKD and heart failure with reduced ejection fraction are therefore at an increased risk of death but paradoxically often receive suboptimal doses of RAAS inhibitors because of fear of inducing hyperkalemia and its consequences, including sudden cardiac death. [2] [3] [4] Although there are several options for the treatment of acute hyperkalemia, options are much limited for the management of chronic hyperkalemia in those patients with heart failure requiring RAAS inhibitors. Outpatient treatment of hyperkalemia is limited by the lack of effective agents. 4 Agents that have been used to manage persistently high K þ levels include diuretics (with or without sodium bicarbonate) and K þ -binding resins such as calcium polystyrene sulfonate and sodium polystyrene sulfonate (SPS). 5, 6 Calcium polystyrene sulfonate and SPS can lead to serious gastrointestinal (GI) adverse events, including colonic necrosis and perforation, [7] [8] [9] [10] which has led to warnings in the prescribing information. [7] [8] [9] In addition, because sodium is the counter exchange ion with SPS, caution is advised when treating patients who cannot tolerate even small increases in sodium load (eg, those with severe congestive heart failure, severe hypertension, or marked edema). 7 Patients with chronic heart failure who develop hyperkalemia therefore often have their dose of RAAS inhibitors reduced or discontinued, 10 thereby exposing them to increased cardiovascular (CV) risk.
Description of the Intervention
Patiromer is an orally administered drug (maximum dose of 50.4 g/d), which can be used for the treatment of hyperkalemia. 11 The active moiety, patiromer, is a non-absorbed polymer that binds K þ throughout the GI tract, thus increasing fecal excretion of K þ and lowering serum K þ levels. 12 How the Intervention Might Work?
Patiromer consists of smooth, spherical beads approximately 100 mm in diameter that does not swell appreciably in liquids. 13 It acts primarily in the distal colon, where the concentration of free K þ is the highest, to increase fecal K þ excretion.
13,14
Why it was Important to do this Review?
Patiromer is used as a K þ binder in patients with hyperkalemia, having CKD stages 3 and 4 or chronic heart failure and receiving RAAS inhibitors, although important potential harms of treatment-related hypokalemia exist. In light of recent studies [15] [16] [17] [18] [19] and other trial data, we aimed to analyze the available evidence for the benefits and harms of oral patiromer. This systematic review and meta-analysis were conducted to evaluate the efficacy and safety of patiromer in comparison with an active comparator or placebo in patients with hyperkalemia or having the risk factors of hyperkalemia.
Methods
Types of Studies
We planned to include all completed randomized controlled trials (RCTs) evaluating patiromer-based interventions versus placebo or any active comparator conducted in patients with established hyperkalemia (serum K þ >5.5 mEq/L) 20 with CKD stages 21 3 and 4 or chronic heart failure 22 or having the risks of hyperkalemia due to medications (K þ sparing diuretics and/or RAAS inhibitors) or other reasons (such as Addison's disease, diabetic nephropathy, and tubulointerstitial diseases). We wanted to include both published and unpublished data (of completed studies) in the English language without imposing any time frame.
Types of Participants
Inclusion criteria. We aimed at including studies enrolling adults with having documented hyperkalemia (serum K þ >5.5 mEq/L) 20 or with the risks of developing hyperkalemia due to coexisting CKD stages 21 3 and 4 or due to medications (K þ sparing diuretics and/or RAAS inhibitors) for chronic heart failure 22 or other reasons (such as Addison's disease, diabetic nephropathy, and tubulointerstitial diseases).
Exclusion criteria. Patients receiving any other K þ lowering drugs as comedications were excluded.
Types of Intervention
We aimed at including the following comparison trials:
1. Patiromer versus placebo or no treatment.
Patiromer versus other active intervention.
We recorded the use of relevant cointerventions such as spironolactone, RAAS inhibitors, and non-RAAS inhibitor antihypertensives.
Types of Outcome Measures
Primary outcomes.
1. All-cause mortality during the treatment period. 2. Reduction in frequency and duration of hospitalization (due to complications of hyperkalemia) and duration of hospital stay during the treatment period. 3. Episodes of hypokalemia or hyperkalemia (normal serum K þ : 3.5-5.5 mEq/L 20 ) during the treatment period. 4. All reported CV and GI adverse events during the treatment period.
Secondary outcomes.
1. Serial change in serum K þ until end of treatment or follow-up during the treatment period. 2. All other reported adverse reactions during the treatment period.
Outcomes having insufficient or limited data were tabulated and assessed using descriptive techniques.
Definition of serious and other (non-serious) adverse events. These are enumerated in Search terms used. "Patiromer," "RLY5016," "RLY 5016," "RLY-5016," "Veltassa," "Potassium," "Potassium binding resin," "Potassium binder," "Potassium lowering therapy," "Potassium lowering treatment," "Hyperkalemia," "Hyperkalaemia," "Hyperpotassaemia," "Hyperpotassemia," "Chronic kidney disease," "Renal," "Heart failure," and "Relypsa, Inc."
Data Collection and Analysis
We planned to perform a meta-analysis of studies fitting into our inclusion and exclusion criteria. If data were insufficient due to less number of studies, we decided to represent the data by descriptive statistics. If no studies were available as per our inclusion criteria, we decided to conduct a meta-analysis of important and relevant excluded studies after disagreement resolution.
Selection of studies. The search strategy described was used to obtain titles and abstracts of studies that might be relevant to this review. Titles and abstracts were screened independently by 2 authors, who discarded studies that were not applicable; however, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and, if necessary, the full text of those studies to determine which studies satisfied the inclusion and exclusion criteria.
Data extraction and management. Data extraction was carried out independently by 2 authors using standard data extraction forms. Studies reported in non-English language journals were not found. Although more than 1 publication of 1 study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Although relevant outcomes were only published in earlier versions, those data were used. Any discrepancies between published versions were highlighted. No filter was applied for funding sources; no assumptions or simplifications were made during searching.
Assessment of risk of bias in included studies. The following items were independently assessed by 2 authors using the risk of bias assessment tool 23 to evaluate the risk of bias in the study outcomes:
Was there adequate sequence generation (selection bias)? Was allocation adequately concealed (selection bias)? Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? Were incomplete outcome data adequately addressed (attrition bias)? Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? Was the study apparently free of other problems that could put it at a risk of bias?
Measures of treatment effect. For dichotomous outcomes (eg, death and adverse events), results were expressed as risk ratio with 95% confidence intervals. Although continuous scales of measurement were used to assess treatment effects (eg, serial change in serum K þ ), the mean difference was used.
Meta-analysis. We combined our primary and secondary outcome data (where full data are available in related studies) in Review Manager (RevMan) version 5.3.5.
Unit of analysis issues. We tried to take into account the level at which randomization occurred, such as cross-over RCTs, cluster RCTs, and multiple observations for the same outcome. 23 Dealing with missing data. Any further information required from the original author was requested by written correspondence (eg, emailing and writing to corresponding author). Evaluation of important numerical data such as screened, randomized patients as well as intention-to-treat, as-treated, and perprotocol population was carefully performed. Attrition rates, for example, dropouts, losses to follow-up, and withdrawals, were investigated. Issues of missing data and imputation methods (eg, last observation carried forward) were critically appraised. 23 Assessment of heterogeneity. Heterogeneity was analyzed using a w 2 test on N-1 degrees of freedom, with an a of .05 used for statistical significance and with the i 2 test 24 ; i 2 values of 25%, 50%, and 75% corresponded to low, medium, and high levels of heterogeneity, respectively.
Assessment of reporting biases. Funnel plots were used to assess the potential existence of small study effects. 23 Data synthesis. Fixed effect model was used to analyze the efficacy outcome, and random effect model was used to analyze adverse events for conservative estimate. This was done to ensure robustness of the model chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity. If data were available, subgroup analysis was decided to be used to explore possible sources of heterogeneity.
Sensitivity analysis. We decided to perform sensitivity analyses in order to explore the influence of the following factors on effect size:
Repeating the analysis excluding unpublished studies. Repeating the analysis taking account of the risk of bias. Repeating the analysis excluding any very long or large studies to establish how much they dominate the results. Repeating the analysis excluding studies in which randomized cointerventions are not equal between study groups.
Results
After screening the databases, a total of 6 potential studies were identified, and of those, 3 studies matched our inclusion and exclusion criteria (Figure 1 ). There were no randomized activecontrolled or placebo-controlled studies checking the efficacy and safety of patiromer in patients with documented hyperkalemia (serum K þ >5.5 mEq/L) 20 due to CKD, heart failure, or any other causes. One study was a single-arm study evaluating patiromer titration in heart failure patients with CKD, 15 and another was a terminated, open-label, multiple dose study to evaluate the pharmacology, safety, and tolerability of patiromer in participants on hemodialysis. 19 These 2 studies were excluded (detailed study design with duration is provided in the Supplemental file). An ongoing incomplete trial has also been excluded. The details of the included studies have been included in the Supplemental file.
The third study by Bakris et al 17 evaluated the effect of patiromer on serum K þ level in patients with hyperkalemia and diabetic kidney disease, but there was no active comparator or placebo. The fourth study by Pitt et al 18 evaluated the efficacy and safety of patiromer in a double-blind, placebo-controlled study in patients with chronic heart failure, who were at the risk of developing hyperkalemia due to the treatment of heart failure (eg, RAAS inhibitors). Weir et al 16 conducted a 2-phase study with patiromer in patients with kidney disease and hyperkalemia, receiving RAAS inhibitors. In part A, there was no active comparator or placebo, and in part B, all the patients were normokalemic at baseline but still were at the risk of developing hyperkalemia due to coexisting CKD (detailed study design with duration is provided in the Supplemental file). Figure 2 depicts the risk of bias assessment based on the parameters mentioned above.
Heterogeneity was observed with some of the parameters. Subgroup analysis could not be done for heterogeneity owing to insufficient data. Sensitivity analysis was also not possible to conduct in the meta-analysis owing to very insufficient data.
Patiromer Versus Placebo
The results of the meta-analysis of primary and secondary outcomes of 2 studies (Pitt et al 18 and Weir et al; [part A]) 16 are provided in Figures 3 and 4 . Subtotal analysis was not shown where heterogeneity was high. Tables 2 and 3 enumerate different efficacy parameters and Table 4 enumerates different adverse events data, which are not included in the metaanalysis owing to insufficiency.
Primary outcomes. The dose of patiromer in the trial by Pitt et al 18 and Weir et al (part A) 16 was 30 g/d and 8.4 to 16.8 g/d, respectively. There was a non-significant improvement in all-cause mortality risk during the treatment period with patiromer than placebo. There was no data on hospitalization. There was also a non-significant improvement in serious CV events with placebo than patiromer. Pitt et al 18 did not look for non-serious CV adverse events, which was however more frequent with placebo (5.77%) than patiromer (0%) in the study by Weir et al (part A). 16 Serious GI events were more common with placebo (1.92%) than patiromer (0%) as shown by Weir et al (part A) 16 ; however, this adverse event was not included in the study by Pitt et al. 18 The meta-analysis also showed that there was a significant (P ¼ .02) reduction in the risk of nonserious GI events with placebo than patiromer. In the study by Pitt et al, 18 the proportion of patients with hyperkalemia (serum K þ >5.5 mEq/L) was more in the placebo group (24.5%) than the patiromer group (7.3%) at day 28. In the same study, more participants discontinued the study due to hyperkalemia (serum K þ >5.5 mEq/L) in the placebo arm (6.1%) as compared to the patiromer arm (0%). In the study by Weir et al (part A), 16 the proportion of patients with hyperkalemia (serum K þ >5.49 mEq/L) at day 56 was more in the placebo group (60%) than the patiromer group (15%). None of these studies looked for episodes of hypokalemia during the treatment period.
Secondary outcomes. Patiromer reduced serum K
þ better than placebo on day 28 of the treatment or till the time of first titration of dose in both these 2 studies. Patiromer was not significantly better in reducing the risks of all serious and nonserious adverse events as compared to placebo. There was high heterogeneity in the meta-analysis with other adverse events (i 2 ¼ 85%). 
Low-Dose Versus High-Dose Patiromer
The results of the meta-analysis of primary and secondary outcomes of 2 studies (Bakris et al 17 Tables 5 and 6 enumerate different efficacy parameters and Table 4 enumerates different adverse events data, which are not included in the metaanalysis owing to insufficiency. by Weir et al (part B) 16 were 8.4 g/d and 16.8 g/d, respectively. There was a non-significant improvement in all-cause mortality risk during the treatment period with low-dose than high-dose patiromer in the trial by Bakris et al. 17 However, mortality in the follow-up period in the same study could not be accounted in the meta-analysis for lack of subgroup data. Also, there was no mortality in either groups in the other study by Weir et al (part B). 16 There were no data on hospitalization. There were non-significant improvements in both serious and non-serious CV and GI events in both these studies with low dose as compared to the high dose.
None of these studies looked for episodes of hyperkalemia or hypokalemia during the treatment period.
Secondary outcomes. Patiromer with the high dose did not significantly reduced serum K þ better than the low dose on day 28 of the treatment or till the time of first titration of dose in both these 2 studies. In the study by Bakris et al, 17 the high dose was associated with better lowering of serum K þ in serial measurements. The low dose of patiromer reduced the risks of all nonserious miscellaneous (pruritus, fatigue, and headache) events significantly (P ¼ .04) than the high dose. However, the low dose did not reduce all non-serious metabolic adverse events significantly than the high dose. Also, as compared to the high dose, the low dose had a non-significant lower reduction in the risks of all serious adverse events, all serious infections and inflammations, all serious renal adverse events, and all nonserious renal adverse events. There was high heterogeneity in the meta-analysis with serious adverse renal events (i 2 ¼ 67%), other adverse events (i 2 ¼ 87%), and other metabolic adverse events (i 2 ¼ 75%).
Discussion
By this work, we have tried to analyze the efficacy and safety of patiromer in treating hyperkalemia (serum K þ >5.5 mEq/L) due to coexisting CKD stages 3 and 4 or due to medications (K þ sparing diuretics and/or RAAS inhibitors) for chronic heart failure or other reasons (such as Addison's disease, diabetic nephropathy, and tubulointerstitial diseases). The United States Food and Drug Administration approved patiromer in October 2015 to treat hyperkalemia. 11 As of now, there is no published meta-analysis or systematic review on this drug. 
Relevance of the Work in the Light of Present Knowledge
Hyperkalemia is a serious medical condition that can cause severe cardiac electrophysiology alterations, such as cardiac arrhythmias and sudden death. It results mainly from CKD and medications used for heart failure (such as RAAS inhibitors). It is an independent risk factor for early mortality and increased hospitalization. 25 It has been also demonstrated that tissue necrosis, K þ supplementation, metabolic acidosis, calcium gluconate for treatment of hyperkalemia, acute kidney injury, and prolonged duration of hyperkalemia are independent predictors of in-hospital mortality and morbidity. 26 For these reasons, we decided to look for all-cause mortality and duration of hospitalization (due to complications of hyperkalemia) as our primary outcome. Drastic reduction in serum K þ is also dangerous for the risk of sudden cardiac death; it is often beneficial to keep the serum K þ level near the upper normal range in patients with long-standing hyperkalemia. 27 Existing therapy for hyperkalemia such as SPS has been associated with colonic necrosis and mucosal injury of the upper GI tract. 28, 29 In terms of efficacy, there was also no convincing evidence that SPS increases fecal K þ losses in experimental animals or humans, and also no evidence was found that adding sorbitol to the resin increases its effectiveness as a treatment for hyperkalemia. 8 So in our study, we also wanted to look for any CV or GI adverse events in our primary outcome with patiromer, and we included all reported serial changes in serum K þ during the trial period as well as other adverse events in the secondary outcome.
Key Findings
We could not find any RCTs comparing the efficacy and safety of patiromer versus placebo or active comparator in patients with documented hyperkalemia. Either patients were normokalemic at screening (only having the risks of hyperkalemia owing to the concomitant medications) or no active comparator or placebo was used. Although Bakris et al mentioned the limitations of using an active comparator (SPS having the GI adverse reports) or placebo (potentially dangerous and hence unethical), we think using an alternative calcium-based resin, 30, 31 having lesser risks of GI adverse events for a shorter period, would frame a more convincing study design.
From our systematic review and meta-analysis, we could not comment on any significant improvement in all-cause mortality with patiromer than placebo, nor with one dose of patiromer than another dose. There were no data of hospitalization in either of the studies. There was also a non-significant improvement in serious CV events with placebo than patiromer. Although serious GI events were more common with placebo, there was a significant reduction in the risk of non-serious GI events with placebo. As expected, patiromer lowered serum K þ more than placebo and there were more patients developing hyperkalemia in the placebo arm compared to the patiromer arm. We also found that the low dose of patiromer had a non-significant mortality benefits than the high dose, and again as expected, the high dose was associated with somewhat better efficacy and increased the risks of several adverse events. However, the better efficacy (lowering of serum K þ ) with high dose might not be clinically significant when compared against the respective adverse events.
Other Salient Points
As mentioned earlier, the baseline serum K þ levels were different in different studies. However, all the studies included patients with CKD, heart failure, diabetes mellitus, and hypertension. The common confounding medications were RAAS inhibitors, spironolactone, and non-RAAS inhibitor antihypertensive agents. The methods used in dealing with missing data (intention to treat analysis and last observation carried forward) in these studies were all justified. In the studies by Weir et al (parts A and B) 16 and Bakris et al, 17 although the starting dose of patiromer was fixed, there was a prespecified algorithm of changing the dose (range: 0-50.4 g/d) in due course of treatment to keep the serum K þ level within normal range. On the other hand, in the study by Pitt et al, 18 patiromer was administered at a fixed dose throughout the treatment, but the dose of spironolactone could be adjusted by a predefined algorithm to keep the serum K þ level within normal range. So, the outcomes might have been influenced by the specific dose administered. In the study by Weir et al, 16 patients receiving 2 different doses of patiromer in part A were continued in part B to receive either patiromer or placebo. There was no washout period (half-life of patiromer: 3-4 days 32 ) in between. The inclusion criteria of part B of Weir et al's16 study (patients with moderate-severe hyperkalemia at baseline of part A) might be responsible for the marked heterogeneity in some of the parameters of this study excluded (detailed study design with duration is provided in the Supplemental file).
Limitations of the Study
To include in our meta-analysis, we sought for the patient-wise distribution of patiromer dose (as it was variable and subjected to titration), the corresponding confounders (eg, spironolactone dose) and the corresponding outcomes (primary and secondary). But those were not available in the published articles [16] [17] [18] or published trial protocols, [16] [17] [18] and although we communicated with the authors and sponsors of the trials, we could not obtain those. This might have some potential confounding effects and was reflected in the heterogeneity in some of the parameters. Another limitation of our study was that, because of insufficient data, we could not do any subgroup analysis (for heterogeneity) or sensitivity analysis. Also, there was an overlap in the low and high doses of patiromer as used in the trial by Bakris et al 17 and Weir et al (part B), 16 and we could not separately analyze the subgroups due to limited data.
Implications for Future Practice
Based on our findings, we can conclude that patiromer does not provide any significant advantage over placebo in patients with hyperkalemia or having the risk factors of hyperkalemia. Also, the high dose of patiromer does not provide any significant advantage over the low dose in several efficacy and safety parameters when used in similar cohort of patients.
Implications for Future Research
We recommend conducting RCTs with patients having hyperkalemia and evaluate patiromer against an active comparator (eg, calcium-based resin). It is noteworthy that an open-label, randomized, parallel group phase-4 study of the efficacy and safety of patiromer for oral suspension with or without food for the treatment of hyperkalemia is in progress (detailed study design with duration is provided in the Supplemental file). 33 
Conclusion
Although patiromer seems promising in terms of efficacy and safety in multiple clinical trials, more RCTs with active comparator or existing standard of care in patients with established hyperkalemia are essential to come to a consensus about the indication and proper use of patiromer.
